Contribute Try STAT+ Today

Amid ongoing concerns that clinical trial data is too often kept under wraps, an analysis found that most large drug makers continue to do a poor job of sharing study data after new medicines were approved, adding further pressure on the pharmaceutical industry to improve disclosure practices.

Specifically, just three of a dozen companies shared data within a reasonable time frame, according to the analysis published in BMJ. The researchers, who reviewed disclosures for new medicines that were approved in 2015, noted the proportion rose to four after the laggards were given 30 days to make changes. And only four of the companies registered and reported or published the results of all of their trials conducted in patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.